Recruiting | Phase III
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
The purpose of this study is to compare the usual treatment plus placebo to the usual treatment plus Atezolizumab.
- Group 1: Treated with paclitaxel, trastuzumab, pertuzumab, and placebo
- Group 2: Treated with paclitaxel, trastuzumab, pertuzumab, and atezolizumab
Key Participation Requirements:
Male or Female
19 years and older
Adenocarcinoma of the breast
HER2- positive breast cancer
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.